Recognizing AIM’s February Advocate of the Month: Pamela Talley

Biogen’s Decision to Discontinue Alzheimer’s Drug

To Improve the Early Detection and Diagnosis of Alzheimer’s, States Need to Ensure Access to Biomarker Testing